VANCOUVER, BC, Feb. 3, 2025 /PRNewswire/ — A market analysis made by Moore Financial Consulting published today estimate the global market for Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) (the “Company” or “ZCT”), an Israeli FemTech medical device company focused on revolutionizing women’s health, will reach over USD 2 billion by 2030, with a compound annual growth rate of 5.25% globally and 3.9% in North America and 4.2% in Europe.
- Zero Candida
Moore Market analysis: Zero Candida potential market will reach over $2 Billion by 2030
Public Announcements
- Zero Candida
Zero Candida Technologies Reports Full Year 2024 Financial Results and Business Highlights
VANCOUVER, BC, April 2, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device…
- Zero Candida
Zero Candida Commences Trading on OTCQB Market
VANCOUVER, BC, March 12, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device…
- Zero Candida
Moore Market analysis: Zero Candida potential market will reach over $2 Billion by 2030
VANCOUVER, BC, Feb. 3, 2025 /PRNewswire/ — A market analysis made by Moore Financial Consulting published today estimate the global market for Zero Candida Technologies,…
- Zero Candida
Zero Candida Technologies Reports Full Year 2024 Financial Results and Business Highlights
VANCOUVER, BC, April 2, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device…
- Zero Candida
Zero Candida Commences Trading on OTCQB Market
VANCOUVER, BC, March 12, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device…
- Zero Candida
Zero Candida Announces Successful Listing on Frankfurt Stock Exchange and Details of Investor Webinar
VANCOUVER, BC, Jan. 16, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) (the “Company” or “ZCT”), an Israeli FemTech medical device company…
- Zero Candida
Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025
VANCOUVER, BC, January 06, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) (the “Company” or “ZCT”), an Israeli FemTech medical device company…
- Zero Candida
Zero Candida Receives South African Patent for its ZC- 01 device
VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ — Zero Candida (the “Company” or “ZC”) (TSXV: ZCT), an Israeli FemTech medical device start-up, is pleased to announce…
- Zero Candida
Zero Candida Announces Full Transaction and Being Trading November 25th on the TSX Venture Exchange (Canada)
VANCOUVER, BC, Nov. 25, 2024 /PRNewswire/ — Zero Candida (the “Company” or “ZCT”), (TSXV: ZCT) an Israeli FemTech medical device start-up, is pleased to announce…
- Zero Candida
Zero Candida Announces TSX Venture Exchange Listing Date
Zero Candida (formerly 1319743 B.C. Ltd.), has recently completed its business acquisition of Zero Candida Ltd., an Israeli private company (“ZC” and “Acquisition” respectively). In…
- Zero Candida
Zero Candida Applies to List its Shares on the TSX Venture Exchange
VANCOUVER, BC, Nov. 18, 2024 /PRNewswire/ — Zero Candida Technologies Inc. (the “Company” or “Zero Candida”) (TSXV: ZCT), a technology company focused on development and…
- Zero Candida
Zero Candida Announces First Intellectual Property in South Africa
Company is in the process to be listed on the TSX Venture Exchange (Canada) at a Proposed Valuation of 40 million Canadian Dollars TEL AVIV,…
- Zero Candida
Zero Candida Announces its Intent to Complete Listing of its Shares on the TSX Venture Exchange (Canada) at a Proposed Valuation of 40 million Canadian Dollars
TEL AVIV, Israel, June 3, 2024 /CNW/ — Zero Candida (the “Company” or “ZC “) an Israeli FemTech medical device start-up is pleased to announce…
